Placebo News and Research

RSS

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.

13 May 2011

Aradigm first quarter total revenue decreases to $0.2 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2011.

12 May 2011

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

12 May 2011

Viewpoints: Tea Party on entitlement reform; Boehner's 'trillions' demand; California's silver tsunami

In a speech on Monday, the speaker of the House said that Republicans would insist on trillions of dollars in spending cuts in exchange for votes to raise the debt limit. He did not mention a time frame. He also did not offer specifics on how he planned to make those cuts. After the beating Republicans took for their plan to slash Medicare, he clearly decided generalities were politically safer. There is no way to solve the country's fiscal ills without an accurate diagnosis and rigorous prescriptions for a cure. Mr. Boehner's speech was devoid of both.

12 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

New drug targets bile acid to provide relief from constipation

Constipation is definitely not a glamorous topic. In reality, it affects nearly 30 million Americans and costs more than $1 billion annually to evaluate and treat. While not often life threatening, the pain, bloating, discomfort, and straining associated with constipation lead sufferers to focus on one thing - relief.

11 May 2011

New Crohn’s disease therapy on its way

In a new study on a drug called Stelara (ustekinumab) it was seen that 40% patients with moderate to severe Crohn's disease responded. Stelara, which is already approved to treat psoriasis, is a human interleukin (IL)-12 and IL-23 antagonist marketed by Centocor Ortho Biotech Inc. The study findings were presented at Digestive Disease Week 2011.

11 May 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments.

10 May 2011

Psychological distress affects IVF outcomes

There is no doubt that undergoing infertility treatment is stressful, with high rates of anxiety and depression reported by many patients. Mind/body therapies designed to help women reduce stress earlier in the treatment process result in higher pregnancy rates, but little is known specifically about the impact of these therapies on women undergoing in vitro fertilization (IVF).

10 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

Placebo News and Research

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

Aradigm first quarter total revenue decreases to $0.2 million

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Viewpoints: Tea Party on entitlement reform; Boehner's 'trillions' demand; California's silver tsunami

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Naurex announces completion of $18 million Series A financing

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Inovio first quarter total revenue increases to $3.1 million for 2011

New drug targets bile acid to provide relief from constipation

New Crohn’s disease therapy on its way

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Psychological distress affects IVF outcomes

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

OncoGenex first quarter revenue decreases to $1.2 million

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News